577 related articles for article (PubMed ID: 11469927)
61. The use of selective estrogen receptor modulators and selective estrogen receptor down-regulators in breast cancer.
Howell SJ; Johnston SR; Howell A
Best Pract Res Clin Endocrinol Metab; 2004 Mar; 18(1):47-66. PubMed ID: 14687597
[TBL] [Abstract][Full Text] [Related]
62. Raloxifene in breast cancer prevention.
Gennari L; Merlotti D; Paola VD; Nuti R
Expert Opin Drug Saf; 2008 May; 7(3):259-70. PubMed ID: 18462184
[TBL] [Abstract][Full Text] [Related]
63. The STAR trial: evidence for raloxifene as a breast cancer risk reduction agent for postmenopausal women.
Bevers TB
J Natl Compr Canc Netw; 2007 Sep; 5(8):719-24. PubMed ID: 17927929
[TBL] [Abstract][Full Text] [Related]
64. Breast cancer prevention.
Powles TJ
Oncologist; 2002; 7(1):60-4. PubMed ID: 11854547
[TBL] [Abstract][Full Text] [Related]
65. The role of selective estrogen receptor modulators on breast cancer: from tamoxifen to raloxifene.
Lee WL; Cheng MH; Chao HT; Wang PH
Taiwan J Obstet Gynecol; 2008 Mar; 47(1):24-31. PubMed ID: 18400579
[TBL] [Abstract][Full Text] [Related]
66. [Raloxifene and breast: from the SERMs concept to its place in clinical practice].
This P; Guyot B
Gynecol Obstet Fertil; 2004 Jan; 32(1):75-84. PubMed ID: 14736604
[TBL] [Abstract][Full Text] [Related]
67. Tamoxifen, raloxifene and the prevention of breast cancer.
Bentrem DJ; Craig Jordan V
Minerva Endocrinol; 2002 Jun; 27(2):127-39. PubMed ID: 11961504
[TBL] [Abstract][Full Text] [Related]
68. Chemoprevention of breast cancer and the trials of the National Surgical Adjuvant Breast and Bowel Project and others.
Smith RE; Good BC
Endocr Relat Cancer; 2003 Sep; 10(3):347-57. PubMed ID: 14503912
[TBL] [Abstract][Full Text] [Related]
69. [Current status of breast cancer chemoprevention].
Oliveira VM; Aldrighi JM; Rinaldi JF
Rev Assoc Med Bras (1992); 2006; 52(6):453-9. PubMed ID: 17242785
[TBL] [Abstract][Full Text] [Related]
70. Continued breast cancer risk reduction in postmenopausal women treated with raloxifene: 4-year results from the MORE trial. Multiple outcomes of raloxifene evaluation.
Cauley JA; Norton L; Lippman ME; Eckert S; Krueger KA; Purdie DW; Farrerons J; Karasik A; Mellstrom D; Ng KW; Stepan JJ; Powles TJ; Morrow M; Costa A; Silfen SL; Walls EL; Schmitt H; Muchmore DB; Jordan VC; Ste-Marie LG
Breast Cancer Res Treat; 2001 Jan; 65(2):125-34. PubMed ID: 11261828
[TBL] [Abstract][Full Text] [Related]
71. The STAR (Study of Tamoxifen and Raloxifene) trial in West Virginia.
Jubelirer SJ; Crowell EB
W V Med J; 2000; 96(6):602-4. PubMed ID: 11194089
[TBL] [Abstract][Full Text] [Related]
72. [Additional effect of SERM: mammary gland].
Kurebayashi J
Clin Calcium; 2004 Oct; 14(10):47-51. PubMed ID: 15577131
[TBL] [Abstract][Full Text] [Related]
73. Potential of selective estrogen receptor modulators as treatments and preventives of breast cancer.
Peng J; Sengupta S; Jordan VC
Anticancer Agents Med Chem; 2009 Jun; 9(5):481-99. PubMed ID: 19519291
[TBL] [Abstract][Full Text] [Related]
74. Tamoxifen prevention of breast cancer: an instance of the fingerpost.
Lippman SM; Brown PH
J Natl Cancer Inst; 1999 Nov; 91(21):1809-19. PubMed ID: 10547388
[No Abstract] [Full Text] [Related]
75. Cardiovascular effects of tamoxifen in women with and without heart disease: breast cancer prevention trial. National Surgical Adjuvant Breast and Bowel Project Breast Cancer Prevention Trial Investigators.
Reis SE; Costantino JP; Wickerham DL; Tan-Chiu E; Wang J; Kavanah M
J Natl Cancer Inst; 2001 Jan; 93(1):16-21. PubMed ID: 11136837
[TBL] [Abstract][Full Text] [Related]
76. American Society of Clinical Oncology technology assessment on breast cancer risk reduction strategies: tamoxifen and raloxifene.
Chlebowski RT; Collyar DE; Somerfield MR; Pfister DG
J Clin Oncol; 1999 Jun; 17(6):1939-55. PubMed ID: 10561236
[TBL] [Abstract][Full Text] [Related]
77. Safety and efficacy of antiestrogens for prevention of breast cancer.
Reddy P; Chow MS
Am J Health Syst Pharm; 2000 Jul; 57(14):1315-22; quiz 1323-5. PubMed ID: 10918921
[TBL] [Abstract][Full Text] [Related]
78. Endogenous sex hormones, breast cancer risk, and tamoxifen response: an ancillary study in the NSABP Breast Cancer Prevention Trial (P-1).
Beattie MS; Costantino JP; Cummings SR; Wickerham DL; Vogel VG; Dowsett M; Folkerd EJ; Willett WC; Wolmark N; Hankinson SE
J Natl Cancer Inst; 2006 Jan; 98(2):110-5. PubMed ID: 16418513
[TBL] [Abstract][Full Text] [Related]
79. Anti-oestrogenic chemoprevention of breast cancer-the need to progress.
Powles TJ
Eur J Cancer; 2003 Mar; 39(5):572-9. PubMed ID: 12628835
[TBL] [Abstract][Full Text] [Related]
80. Chemoprevention of breast cancer.
Osborne MP
Surg Clin North Am; 1999 Oct; 79(5):1207-21. PubMed ID: 10572559
[TBL] [Abstract][Full Text] [Related]
[Previous] [Next] [New Search]